| Lia Pender, FNP | |
|
3119 Woodman Dr, Altoona, WI 54720-2668 | |
| (920) 496-4700 | |
| Not Available |
| Full Name | Lia Pender |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 3119 Woodman Dr, Altoona, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356068662 | NPI | - | NPPES |
| 100224934 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 13324-33 (Wisconsin) | Primary |
| Entity Name | Prevea Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306869276 PECOS PAC ID: 0042123150 Enrollment ID: O20031106000034 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Marshfield Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952347981 PECOS PAC ID: 2264345206 Enrollment ID: O20031106000590 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Beaver Dam Community Hospitals Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972188555 PECOS PAC ID: 2567370539 Enrollment ID: O20040210000666 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346239373 PECOS PAC ID: 2365433224 Enrollment ID: O20040519001426 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1700963048 PECOS PAC ID: 9032029871 Enrollment ID: O20070828000478 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Sacred Heart Hospital Of The Hospital Sisters-3rd Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619355351 PECOS PAC ID: 8729072418 Enrollment ID: O20150814013380 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093221434 PECOS PAC ID: 5698071173 Enrollment ID: O20180208000096 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Lakeview Medical Center Inc Of Rice Lake |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093201832 PECOS PAC ID: 6103737820 Enrollment ID: O20180817001484 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Mchs Hospitals Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1952890873 PECOS PAC ID: 5698071173 Enrollment ID: O20180904002962 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Entity Name | Flambeau Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194317966 PECOS PAC ID: 9032029871 Enrollment ID: O20210409000059 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lia Pender, FNP 3119 Woodman Dr, Altoona, WI 54720-2668 Ph: (920) 496-4700 | Lia Pender, FNP 3119 Woodman Dr, Altoona, WI 54720-2668 Ph: (920) 496-4700 |
News Archive
For some patients with acute coronary syndromes, the strategy of immediate intervention at a medical center does not appear to result in differences in outcomes in comparison with an intervention performed the next working day, according to a study in the September 2 issue of JAMA.
Standard treatment for prostate cancer can include chemotherapy that targets receptors on cancer cells. However, drug-resistant cancer cells can emerge during chemotherapy, limiting its effectiveness as a cancer-fighting agent. Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of prostate cancer, but also can kill cancerous cells.
A new study by researchers at the Department of Environmental Science and Engineering, Xi'an Jiaotong University, China and published in the journal Ecotoxicology and Environmental Safety suggests that respiratory pathogens can not only fall on the fabric covers but can also penetrate the outer cover and go into the microfiber stuffing.
The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY trial.
› Verified 7 days ago
Nancy Ferrara-france, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1511 Daniels Ave, Altoona, WI 54720 Phone: 715-563-4016 | |
Amber Willmarth, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1451 Bluestem Blvd Ste F, Altoona, WI 54720 Phone: 715-575-5800 | |
Tracy Neises, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1411 Winchester Way Ste 7, Altoona, WI 54720 Phone: 715-313-0871 | |
Elise Jane Jensen, DNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1200 Oakleaf Way, Altoona, WI 54720 Phone: 715-832-1400 | |
Jolene L. D'huyvetter, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1200 Oakleaf Way, Suite A, Altoona, WI 54720 Phone: 715-832-1400 Fax: 715-832-4187 | |
Benjamin G Anderson, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1200 Oakleaf Way Ste A, Altoona, WI 54720 Phone: 715-832-1400 Fax: 715-832-4187 |